Taysha Gene Therapies Stock (NASDAQ:TSHA)
Previous Close
$1.27
52W Range
$1.05 - $4.32
50D Avg
$1.58
200D Avg
$1.94
Market Cap
$241.90M
Avg Vol (3M)
$2.05M
Beta
0.94
Div Yield
-
TSHA Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GOSS | Gossamer Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ALEC | Alector, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CABA | Cabaletta Bio, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| GLUE | Monte Rosa Therapeutics, Inc. |
| BMEA | Biomea Fusion, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| INZY | Inozyme Pharma, Inc. |
| STTK | Shattuck Labs, Inc. |